Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Copyright © 2022 Massachusetts Medical Society..
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation.
METHODS: In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma. The primary end point was progression-free survival as assessed by blinded independent central review.
RESULTS: The median progression-free survival was 10.1 months (95% confidence interval [CI], 6.4 to 15.7) with relatlimab-nivolumab as compared with 4.6 months (95% CI, 3.4 to 5.6) with nivolumab (hazard ratio for progression or death, 0.75 [95% CI, 0.62 to 0.92]; P = 0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab-nivolumab group and in 9.7% of patients in the nivolumab group.
CONCLUSIONS: The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).
| Errataetall: |
CommentIn: N Engl J Med. 2022 Jan 6;386(1):91-92. - PMID 34986291 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 386(2022), 1 vom: 06. Jan., Seite 24-34 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tawbi, Hussein A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 21.04.2023 published: Print ClinicalTrials.gov: NCT03470922 CommentIn: N Engl J Med. 2022 Jan 6;386(1):91-92. - PMID 34986291 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2109970 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335216765 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335216765 | ||
| 003 | DE-627 | ||
| 005 | 20231225225340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2109970 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335216765 | ||
| 035 | |a (NLM)34986285 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tawbi, Hussein A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 21.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03470922 | ||
| 500 | |a CommentIn: N Engl J Med. 2022 Jan 6;386(1):91-92. - PMID 34986291 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation | ||
| 520 | |a METHODS: In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma. The primary end point was progression-free survival as assessed by blinded independent central review | ||
| 520 | |a RESULTS: The median progression-free survival was 10.1 months (95% confidence interval [CI], 6.4 to 15.7) with relatlimab-nivolumab as compared with 4.6 months (95% CI, 3.4 to 5.6) with nivolumab (hazard ratio for progression or death, 0.75 [95% CI, 0.62 to 0.92]; P = 0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab-nivolumab group and in 9.7% of patients in the nivolumab group | ||
| 520 | |a CONCLUSIONS: The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a relatlimab |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Lymphocyte Activation Gene 3 Protein |2 NLM | |
| 650 | 7 | |a Lag3 protein, human |2 NLM | |
| 700 | 1 | |a Schadendorf, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Lipson, Evan J |e verfasserin |4 aut | |
| 700 | 1 | |a Ascierto, Paolo A |e verfasserin |4 aut | |
| 700 | 1 | |a Matamala, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Castillo Gutiérrez, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Rutkowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Gogas, Helen J |e verfasserin |4 aut | |
| 700 | 1 | |a Lao, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a De Menezes, Juliana Janoski |e verfasserin |4 aut | |
| 700 | 1 | |a Dalle, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Arance, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Grob, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Shivani |e verfasserin |4 aut | |
| 700 | 1 | |a Abaskharoun, Mena |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Keidel, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Simonsen, Katy L |e verfasserin |4 aut | |
| 700 | 1 | |a Sobiesk, Anne Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Hodi, F Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Georgina V |e verfasserin |4 aut | |
| 700 | 0 | |a RELATIVITY-047 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Bellaquero, Luciana |e investigator |4 oth | |
| 700 | 1 | |a Casalnuovo, Monica |e investigator |4 oth | |
| 700 | 1 | |a Cinat, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Greco, Martin |e investigator |4 oth | |
| 700 | 1 | |a Minatta, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Hill, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Khattak, Muhammad |e investigator |4 oth | |
| 700 | 1 | |a Long, Georgina |e investigator |4 oth | |
| 700 | 1 | |a Roy, Amitesh |e investigator |4 oth | |
| 700 | 1 | |a Sandhu, Shahneen |e investigator |4 oth | |
| 700 | 1 | |a Van Der Westhuizen, Andre |e investigator |4 oth | |
| 700 | 1 | |a Atkinson, Victoria |e investigator |4 oth | |
| 700 | 1 | |a Hoeller, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Koelblinger, Peter |e investigator |4 oth | |
| 700 | 1 | |a Richtig, Erika |e investigator |4 oth | |
| 700 | 1 | |a Baurain, Jean-Francois |e investigator |4 oth | |
| 700 | 1 | |a Kruse, Vibeke |e investigator |4 oth | |
| 700 | 1 | |a Neyns, Bart |e investigator |4 oth | |
| 700 | 1 | |a de Azevedo, Sergio |e investigator |4 oth | |
| 700 | 1 | |a de Barros E Silva, Miilton |e investigator |4 oth | |
| 700 | 1 | |a de Melo, Andreia Cristina |e investigator |4 oth | |
| 700 | 1 | |a de Menezes, Juliana |e investigator |4 oth | |
| 700 | 1 | |a Pires de Camargo, Veridiana |e investigator |4 oth | |
| 700 | 1 | |a Schvartsman, Gustavo |e investigator |4 oth | |
| 700 | 1 | |a Wainstein, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Weiss, Bianca |e investigator |4 oth | |
| 700 | 1 | |a Mihalcioiu, Catalin |e investigator |4 oth | |
| 700 | 1 | |a Miller, Wilson |e investigator |4 oth | |
| 700 | 1 | |a Song, Xinni |e investigator |4 oth | |
| 700 | 1 | |a Spreafico, Anna |e investigator |4 oth | |
| 700 | 1 | |a Macfarlane, Robyn |e investigator |4 oth | |
| 700 | 1 | |a Salman, Pamela |e investigator |4 oth | |
| 700 | 1 | |a Matamala, Luis |e investigator |4 oth | |
| 700 | 1 | |a Contreras Mejia, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Cuello, Javier |e investigator |4 oth | |
| 700 | 1 | |a Bastholt, Lars |e investigator |4 oth | |
| 700 | 1 | |a Schmidt, Henrik |e investigator |4 oth | |
| 700 | 1 | |a Svane, Inge Marie |e investigator |4 oth | |
| 700 | 1 | |a Hernberg, Micaela |e investigator |4 oth | |
| 700 | 1 | |a Iivanainen, Sanna |e investigator |4 oth | |
| 700 | 1 | |a Skytta, Tanja |e investigator |4 oth | |
| 700 | 1 | |a Vihinen, Pia |e investigator |4 oth | |
| 700 | 1 | |a Arnault, Jean-Philippe |e investigator |4 oth | |
| 700 | 1 | |a Dalle, Stephane |e investigator |4 oth | |
| 700 | 1 | |a Dutriaux, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Grob, Jean-Jacques |e investigator |4 oth | |
| 700 | 1 | |a Hainaut-Wierzbicka, Ewa |e investigator |4 oth | |
| 700 | 1 | |a Lebbe, Celeste |e investigator |4 oth | |
| 700 | 1 | |a Lesimple, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Mortier, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Eigentler, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Gesierich, Anja |e investigator |4 oth | |
| 700 | 1 | |a Gutzmer, Ralf |e investigator |4 oth | |
| 700 | 1 | |a Hassel, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Herbst, Rudolf |e investigator |4 oth | |
| 700 | 1 | |a Krackhardt, Angela |e investigator |4 oth | |
| 700 | 1 | |a Mauch, Cornelia |e investigator |4 oth | |
| 700 | 1 | |a Mohr, Peter |e investigator |4 oth | |
| 700 | 1 | |a Pfoehler, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Schadendorf, Dirk |e investigator |4 oth | |
| 700 | 1 | |a Terheyden, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Ulrich, Jens |e investigator |4 oth | |
| 700 | 1 | |a Utikal, Jochen |e investigator |4 oth | |
| 700 | 1 | |a Boukovinas, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Gogas, Helen |e investigator |4 oth | |
| 700 | 1 | |a Drumea, Karen |e investigator |4 oth | |
| 700 | 1 | |a Lotem, Michal |e investigator |4 oth | |
| 700 | 1 | |a Schachter, Jacob |e investigator |4 oth | |
| 700 | 1 | |a Ascierto, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Del Vecchio, Michele |e investigator |4 oth | |
| 700 | 1 | |a Fierro, Maria Teresa |e investigator |4 oth | |
| 700 | 1 | |a Maio, Michele |e investigator |4 oth | |
| 700 | 1 | |a Pigozzo, Jacopo |e investigator |4 oth | |
| 700 | 1 | |a Tondini, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Castillo Gutierrez, Erika |e investigator |4 oth | |
| 700 | 1 | |a Murillo, Emilio |e investigator |4 oth | |
| 700 | 1 | |a Medina Soto, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Molina Alavez, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Torres, Marineé |e investigator |4 oth | |
| 700 | 1 | |a Jackson, Christopher |e investigator |4 oth | |
| 700 | 1 | |a North, Richard |e investigator |4 oth | |
| 700 | 1 | |a Srivastava, Archana |e investigator |4 oth | |
| 700 | 1 | |a Jacobsen, Kari |e investigator |4 oth | |
| 700 | 1 | |a Mackiewicz, Jacek |e investigator |4 oth | |
| 700 | 1 | |a Rutkowski, Piotr |e investigator |4 oth | |
| 700 | 1 | |a Ciuleanu, Tudor |e investigator |4 oth | |
| 700 | 1 | |a Clement, Dana |e investigator |4 oth | |
| 700 | 1 | |a Schenker, Michael |e investigator |4 oth | |
| 700 | 1 | |a Zob, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Demidov, Lev |e investigator |4 oth | |
| 700 | 1 | |a Makarova, Yulia |e investigator |4 oth | |
| 700 | 1 | |a Musaeva, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Arance Fernandez, Ana |e investigator |4 oth | |
| 700 | 1 | |a De La Cruz, Luis |e investigator |4 oth | |
| 700 | 1 | |a Mujika Eizmendi, Karmele |e investigator |4 oth | |
| 700 | 1 | |a Munoz, Eva |e investigator |4 oth | |
| 700 | 1 | |a Quindos, Maria |e investigator |4 oth | |
| 700 | 1 | |a Soria, Ainara |e investigator |4 oth | |
| 700 | 1 | |a Carneiro, Ana |e investigator |4 oth | |
| 700 | 1 | |a Eriksson, Hanna |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 386(2022), 1 vom: 06. Jan., Seite 24-34 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2022 |g number:1 |g day:06 |g month:01 |g pages:24-34 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2109970 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2022 |e 1 |b 06 |c 01 |h 24-34 | ||